Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 339

recruiting
3 983
countries
28
conditions
2 109

10 385 trials match your criteria

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years

Partial seizures

Not yet recruiting

One-Year Open-Label Extension Study Evaluating Safety and Efficacy of Huperzine A as Adjunctive Therapy in Adults with Focal Onset Seizures

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years

Colorectal cancer

Not yet recruiting

A phase 1/2 study evaluating safety, pharmacokinetics and efficacy of SOT109 in patients with advanced unresectable or metastatic colorectal cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years

Schizophrenia

Not yet recruiting

Phase 3 Double‑Blind Relapse Prevention Trial of Trospium Chloride and Xanomeline Tartrate (KarXT) in Adults with Schizophrenia

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years

Renal transplant

Not yet recruiting

Study of anti‑T lymphocyte immunoglobulin (rabbit) in non‑sensitized kidney transplant recipients at high risk of delayed graft function

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years

Prostate cancer

Not yet recruiting

Evaluation of [99mTc]PSMA I&S PET‑Guided Navigation with Electromagnetic Tracking in miN1 Prostate Cancer Patients Undergoing Radio‑Guided Surgery

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:[99MTC]PSMA I&S
Countries:GreeceGreece
  • Participants:0–17 years · Healthy volunteers
  • Substances:Clesrovimab
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Transplant rejection

Not yet recruiting

Evaluating mezagitamab in adults with late antibody-mediated rejection after kidney transplant

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.